RNS Number : 0781D
Pharma C Investments PLC
25 June 2021
Pharma C Investments Plc
("Pharma C" or the "Company")
Board Change, Appointment of Corporate Advisor, Grant of Options and Warrants
Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on ancillary businesses, is pleased to provide the following updates to shareholders.
Appointment of Toby Shillito
Pharma C has appointed Toby Shillito to the Board as Chief Business Development Officer. Toby has over seven years' experience in designing and operating licensed facilities to cultivate medical cannabis in Europe, as well as assessing the value of technological innovations in this space.
Toby established the Cannabis Industry Council's Corporate Responsibility Group in Q2 of this year. He has also founded iGeneration.Life, a pharmaceutical company pursuing Medicines and Healthcare products Regulatory Agency (MHRA) licenses for cannabis based medicinal products in the UK. Toby's vast experience in the medical cannabis industry enables him to identify business models that are likely to succeed in the post-prohibition era, as well as assist cannabis companies to comply with their social and environmental responsibilities.
Current Directorships
Past Directorships
MediCrops Holding AG (Switzerland)
Candour Partners Limited
Suisse Royal Group GmBH (Switzerland)
Sunshine Laboratories Limited
Except as set out above, there is no further information regarding Toby Shillito, that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.
Appointment of Novum Securities Limited as AQSE Corporate Advisor
Pharma C has appointed Novum Securities Limited as its AQSE Corporate Advisor with immediate effect.
Chana Greenberg, CEO of Pharma C Investments, commented, "I am delighted to be welcoming Toby to our Board. His wealth of experience and knowledge in the cultivation of medical cannabis is unmatched and will be invaluable as we look to make our initial investments.
Along with this, I am pleased to welcome Novum Securities as our Corporate Advisor. We look forward to working closely with them as we continue to grow our Company. I would like to personally thank Beaumont Cornish for their exceptional guidance and advice during our AQSE admission earlier this year.
The company is currently looking at a number of potential investments and further announcements will be made in due course."
Grant of Options and Warrants
Pharma C announces that the Company has granted to Gavin Sathianathan (Investment Strategy Director) an aggregate of 12,000,000 options over ordinary shares of 0.7p each in the Company, and has granted to Toby Shillito (Chief Business Development Officer) an aggregate of 5,000,000 options over ordinary shares of 0.7p pence each in the Company (the "Options").
Name of individual
Number of Shares subject to option
Director's interest in the Company's issued share capital (exc. options)
Gavin Sathianathan
12,000,000
8.63%
Toby Shillito
5,000,000
0.00%
The options are exercisable anytime between the first and fifth anniversaries of granting
In total 47.83 million share options are now outstanding representing approximately 17.7 per cent of the Company's current issued share capital. The total number of Ordinary Shares currently in issue is 269,857,144.
In addition, 20,000,000 warrants have been granted exercisable at 0.7 p anytime until the fifth anniversary of grant, in lieu of services provided in connection with the recent Admission to AQSE.
The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation is appended below.
This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).
The Directors of Pharma C Investments plc take responsibility for this announcement.
- Ends -
For additional information please contact:
Pharma C
Tel: +44 7897 834 092
Chana Greenberg, CEO
chana@pharmacinvestments.com
Novum Securities (AQSE Corporate Adviser)
Tel: +44 207 399 9429
David Coffman / Lucy Bowden
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe
tim.blythe@blytheweigh.com
Megan Ray
megan.ray@blytheweigh.com
Pello Capital (Broker)
+44 203 700 2500
Callum Hill
ch@pellocapital.com
About Pharma C Investments
Pharma C Investments is an investment vehicle targeting the legal medicinal cannabis industry globally. The Company is seeking to identify breakout companies within the legal markets with a particular focus on the UK, EU and Israel and will provide capital, strategic insights and operational support. Pharma C is run by cannabis entrepreneurs who understand the unique challenges of the legal cannabis industry and thus can provide invaluable support and expertise for growing companies.
Notification and public disclosure of transaction by person discharging managerial responsibilities
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
1) Gavin Sathianathan 2) Toby Shillito
2
Reason for notification
a.
Position/Status
1) Investment Strategy Director 2) Chief Business Development Officer
b.
Initial notification/ Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
Pharma C Investments plc
b.
LEI
213800CBZ6E6WRDGV387
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Options over Ordinary shares of 0.7p each ISIN Code: GB00BJDPYD55
b.
Nature of the transaction
Grant of Options
c.
Price(s) and volume(s)
Price
Volume
1) 0.7pp
12,000,000
2) 0.7p
5,000,000
d.
Aggregated information - Aggregated Volume - Price
17,000,000 0.7p
e.
Date of the transaction
24 June 2021
f.
Place of the transaction
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXFIMMTMTBTTRB
